PGE 2 alters chromatin through H2A.Z-variant enhancer nucleosome modification to promote hematopoietic stem cell fate.
Audrey SporrijAvik ChoudhuriMeera PrasadBrejnev MuhireEva M FastMargot E ManningJodi D WeissMichelle KohSong YangRobert E KingstonMichael Yevgeniy TolstorukovHans CleversLeonard I ZonPublished in: Proceedings of the National Academy of Sciences of the United States of America (2023)
Prostaglandin E2 (PGE 2 ) and 16,16-dimethyl-PGE 2 (dmPGE 2 ) are important regulators of hematopoietic stem and progenitor cell (HSPC) fate and offer potential to enhance stem cell therapies [C. Cutler et al. Blood 122 , 3074-3081(2013); W. Goessling et al. Cell Stem Cell 8 , 445-458 (2011); W. Goessling et al. Cell 136 , 1136-1147 (2009)]. Here, we report that PGE 2 -induced changes in chromatin at enhancer regions through histone-variant H2A.Z permit acute inflammatory gene induction to promote HSPC fate. We found that dmPGE 2 -inducible enhancers retain MNase-accessible, H2A.Z-variant nucleosomes permissive of CREB transcription factor (TF) binding. CREB binding to enhancer nucleosomes following dmPGE 2 stimulation is concomitant with deposition of histone acetyltransferases p300 and Tip60 on chromatin. Subsequent H2A.Z acetylation improves chromatin accessibility at stimuli-responsive enhancers. Our findings support a model where histone-variant nucleosomes retained within inducible enhancers facilitate TF binding. Histone-variant acetylation by TF-associated nucleosome remodelers creates the accessible nucleosome landscape required for immediate enhancer activation and gene induction. Our work provides a mechanism through which inflammatory mediators, such as dmPGE 2 , lead to acute transcriptional changes and modify HSPC behavior to improve stem cell transplantation.
Keyphrases
- transcription factor
- dna binding
- genome wide identification
- stem cells
- stem cell transplantation
- dna methylation
- genome wide
- binding protein
- liver failure
- single cell
- gene expression
- cell therapy
- cell fate
- oxidative stress
- dna damage
- high dose
- respiratory failure
- hepatitis b virus
- low dose
- risk assessment
- drug delivery
- bone marrow